April 12, 2023 11:27 AM EDT
People

Ae­glea Bio­Ther­a­peu­tics to re­duce head­count to 10, seek strate­gic al­ter­na­tives

Tyler Patchen

News Reporter

Ae­glea Bio­Ther­a­peu­tics rolled out in­ter­im da­ta for its drug for a rare in­her­it­ed dis­or­der, but said it doesn’t sup­port a piv­otal tri­al de­sign as the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times